Female sexual interest drug reaches tipping point with Phase III plans
Pharmaceutical Technology
OCTOBER 10, 2022
In 2019, the agency authorized the use of Vyleesi, an injectable form of bremelanotide, for the same condition. FSIAD is not a biologically validated diagnosis, which is confusing and inaccurate, says Dr. James Simon, clinical professor at George Washington University School of Medicine in Washington DC.
59 
Let's personalize your content